Arbutus Biopharma

Fortrea Announces AI-Driven Partnership with Medidata to Increase Diversity in Clinical Trials

Retrieved on: 
Monday, November 20, 2023
Research, Disease, Clinical trial, Patient, Arbutus Biopharma, EDC, Partnership, Medidata Solutions, SVP, Dassault Group, Pharmaceutical industry

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced a partnership with Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.

Key Points: 
  • DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced a partnership with Medidata , a Dassault Systèmes company and leading provider of clinical trial solutions to the life sciences industry, to use Medidata AI Intelligent Trials to increase access to diverse patients in clinical trials conducted by Fortrea.
  • Fortrea’s use of Medidata AI builds on an existing collaboration between the two companies, expanding on Fortrea's use of Medidata Rave EDC , an advanced, robust, and secure EDC system for clinical trial site, patient and lab data capture and management.
  • "Medidata’s data and interface capabilities will enhance our ability to seamlessly integrate diverse populations into the clinical trial process,” said Fortrea COO and President of Clinical Services Mark Morais.
  • “We are thrilled to work with Medidata as part of Fortrea’s go-forward data strategy.”
    “Fortrea and Medidata share a commitment to advancing clinical trial research and this partnership is poised to reshape the landscape of diversity in clinical trials globally,” said Fareed Melhem, SVP, Medidata AI.

Mural Oncology Launches to Advance Pipeline of Novel Engineered Cytokine Immunotherapies

Retrieved on: 
Wednesday, November 15, 2023
Rubius, IL-2, Mural, Cytokine, Research, General counsel, Alexion, Therapy, Head, Arbutus Biopharma, Jazz Pharmaceuticals, Patient, Doctor of Philosophy, Protein engineering, Bristol Myers Squibb, Pembrolizumab, IL-12, Alkermes (company), Halozyme, AbbVie, MBA, YM Biosciences, El Rubius, Nivolumab, Ipilimumab, ImClone Systems, Mirati Therapeutics, BMS, Financial toxicity, Mucosal melanoma, FRCP, The Celator, Cancer, PROC, GSK plc, Pharmaceutical industry, Vaccine, Management, Exelixis, Merck, Immunogen

DUBLIN, Ireland, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA) today launched as an independent, publicly traded, clinical-stage immuno-oncology company leveraging its core competencies in immune cell modulation and protein engineering to develop novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Mural’s ordinary shares will begin trading on the Nasdaq Global Market tomorrow, November 16th, under the ticker symbol “MURA”.

Key Points: 
  • “Immunotherapies have made a tremendous impact on the treatment of cancers over the past decade,” said Caroline Loew, Ph.D., the Company’s chief executive officer.
  • We believe Mural Oncology can lead the future of immunotherapies for patients.
  • Our protein engineering expertise allows us to reimagine the development of pro-inflammatory cytokine-based therapeutics that could address the key limitations with current cancer immunotherapies.
  • Goodwin Procter LLP and Arthur Cox LLP are serving as legal counsel to Mural Oncology.

HanAll Biopharma's Partner, NurrOn Pharmaceuticals Incorporated Appoints Dr. Almira Chabi, MD, EGMP to Board of Directors

Retrieved on: 
Monday, December 11, 2023
NDA, Regenerative medicine, Neuroprotection, Parkinson's disease, Glaucoma, PD, Artificial intelligence, Patient, Genentech, Arbutus Biopharma, Neurology, Merck, Therapy, Science, Medical research, Drug discovery, Growth, Lead, Pharmaceutical industry, Management, MD, Neuroscience, Ophthalmology

Dr. Chabi has led programs across multiple therapeutic areas including neurology, immunology, oncology, and ophthalmology as well as applications of artificial intelligence.

Key Points: 
  • Dr. Chabi has led programs across multiple therapeutic areas including neurology, immunology, oncology, and ophthalmology as well as applications of artificial intelligence.
  • She is also serving on the Scientific and Medical Research Funding Grants Working Group at the California Institute for Regenerative Medicine.
  • Dr. Chabi expressed enthusiasm about joining NurrOn and shared, "I am honored to be a part of NurrOn's Board of Directors.
  • Dr. Chabi joins an esteemed group of professionals on the NurrOn Board, and her appointment aligns with the company's strategic goals for the future.

Morningstar and PitchBook Introduce New Indexes to Provide Investors with Deeper Insight into Emerging Venture Capital Companies

Retrieved on: 
Wednesday, November 15, 2023
Machine learning, Behavior, Research, Arbutus Biopharma, E-commerce, Artificial intelligence, CFA, PitchBook Data, Family, Fintech, Manufacturing, Computer security, Innovation

The new indexes combine the leading venture company data, analytics and insights from PitchBook, an independent subsidiary of Morningstar, with the indexing expertise of Morningstar Indexes, one of the fastest-growing global index providers.

Key Points: 
  • The new indexes combine the leading venture company data, analytics and insights from PitchBook, an independent subsidiary of Morningstar, with the indexing expertise of Morningstar Indexes, one of the fastest-growing global index providers.
  • The industry vertical indexes are derived from the Morningstar PitchBook Global Unicorn Indexes, originally launched in November 2022, and are each designed to enhance investors' ability to identify, track and better understand compelling thematic venture capital investment segments.
  • Paul Condra – Head of Emerging Technology Research, PitchBook, said: "We're incredibly excited to build on our collaboration with Morningstar Indexes to contribute our industry-leading venture capital data and research expertise to Morningstar Indexes' index methodology.
  • Each of the eleven index themes corresponds to an established emerging technology research practice area and well-followed research analyst on our PitchBook team."

Morningstar and PitchBook Introduce New Indexes to Provide Investors with Deeper Insight into Emerging Venture Capital Companies

Retrieved on: 
Wednesday, November 15, 2023
Machine learning, Behavior, Research, Arbutus Biopharma, E-commerce, Artificial intelligence, CFA, PitchBook Data, Family, Fintech, Manufacturing, Computer security, Innovation

The new indexes combine the leading venture company data, analytics and insights from PitchBook, an independent subsidiary of Morningstar, with the indexing expertise of Morningstar Indexes, one of the fastest-growing global index providers.

Key Points: 
  • The new indexes combine the leading venture company data, analytics and insights from PitchBook, an independent subsidiary of Morningstar, with the indexing expertise of Morningstar Indexes, one of the fastest-growing global index providers.
  • The industry vertical indexes are derived from the Morningstar PitchBook Global Unicorn Indexes, originally launched in November 2022, and are each designed to enhance investors' ability to identify, track and better understand compelling thematic venture capital investment segments.
  • Paul Condra – Head of Emerging Technology Research, PitchBook, said: "We're incredibly excited to build on our collaboration with Morningstar Indexes to contribute our industry-leading venture capital data and research expertise to Morningstar Indexes' index methodology.
  • Each of the eleven index themes corresponds to an established emerging technology research practice area and well-followed research analyst on our PitchBook team."

Kythera Labs Announces $20 Million Funding to Accelerate Growth of its Wayfinder Data Technology Platform

Retrieved on: 
Tuesday, November 7, 2023
Roivant Sciences, RWD, CSO, CIBC, Health care, CCO, Arbutus Biopharma, Entrepreneurship, Research, RWE, Growth, Conference on Semantics in Healthcare and Life Sciences, Partnership, Kythira, Chief commercial officer, Databricks, Datavant, Pharmaceutical industry, Wayfinder

FRANKLIN, Tenn., Nov. 7, 2023 /PRNewswire/ -- Kythera Labs, a leading healthcare technology and data analytics company for the Healthcare and Life Sciences industries, announces $20 Million in Series A and debt financing from BIP Ventures and CIBC. The company will use the funds to support the continued growth and scale of Wayfinder, its data-transforming technology platform, and accelerate the development and adoption of new and existing offerings. Kythera also plans to leverage financing to expand partnerships with industry leaders such as Datavant and Databricks.

Key Points: 
  • The company will use the funds to support the continued growth and scale of Wayfinder, its data-transforming technology platform, and accelerate the development and adoption of new and existing offerings.
  • Kythera Labs' data technology platform, Wayfinder, provides access to real-world healthcare data spanning over 8 years, including over 320 million lives with 29.3 billion encounters.
  • Wayfinder corrects, enhances, and adds new dimensions to healthcare data, using a dynamically improving common data model that facilitates data integration.
  • Roivant Sciences adopted Kythera Labs' platform and refined analytics to more efficiently and accurately support its pre-commercialization activities.

Domino Fall 2023 Release Expands Platform to Fast-Track All Enterprise AI, Including GenAI, Responsibly

Retrieved on: 
Tuesday, October 31, 2023
Titan, Q&A, Meta, Netezza, Synthetic media, Project Jupyter, Arbutus Biopharma, Organization, Amazon Web Services, Generative, LLM, Natural language processing, NVIDIA, Ecosystem, Fiddle, DB2, SAP, OpenAI, AWS, Classification, Safety, AI, IP, IBM, Databricks, SAN, Medical device, Customer service, Copper, Dominoes, Anthropization

SAN FRANCISCO, Oct. 31, 2023 /PRNewswire/ -- Domino Data Lab, provider of the leading Enterprise AI platform trusted by over 20% of the Fortune 100, today announced powerful new capabilities for building AI, including Generative AI (GenAI), rapidly and safely at scale. Its fall 2023 platform release jump-starts GenAI innovation by transforming Domino's AI Project Hub into an AI ecosystem hub with contributions from cutting-edge AI companies, reduces time to value with expanded data connections and code generation tools, and further supports responsible AI with new data source audit capabilities.

Key Points: 
  • "Our fall release gives enterprises the agility they need to innovate and the controls necessary to do so responsibly."
  • Furthering its commitment to support responsible AI, Domino is also introducing new Data Audit Logging integrated into all Domino workflows.
  • New ecosystem-contributed templates in the Domino AI Project Hub and Domino's Jupyter AI conversational assistant all are available in public preview today.
  • Reach out to [email protected] for more details on how Domino partners can submit templated projects to the Domino AI Project Hub.

ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study

Retrieved on: 
Tuesday, October 17, 2023
Ophthalmology, ADHD, Plant, UCSF, University, Medicine, Arbutus Biopharma, Phase, Safety, Medical Center, CNS, University of California, San Francisco, Medical device, Polaris, Patient

(NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers.

Key Points: 
  • (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced an update on the Company's eight-week long ADHD Phase IIb clinical study taking place at the University of California San Francisco (UCSF) Medical Center and five Taiwanese medical centers.
  • Sixty-nine subjects enrolled in the study, 50 completed the study, and 11 are currently undergoing treatment.
  • The Phase IIb clinical study continues the Phase IIa clinical study of ABV-1505.
  • "We received a favorable response from the subjects participating in our ADHD Phase IIb study at all of our sites," said ABVC BioPharma Chief Executive Officer Uttam Patil, Ph.

Global Pharma R&D Insights: Data Report from Leaders Around the World, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, September 6, 2023
Pharmacy, Drug discovery, Corporate development, PPD, RWE, DevOps, Global Medical Excellence Cluster, Drug development, MD, Thermo Fisher Scientific, Geography, Fine chemical, Pharmaceutical industry, Arbutus Biopharma

TORONTO, Sept. 6, 2023 /PRNewswire/ -- The future for drug developers is defined by how effectively they adopt innovative pharma R&D strategies and new technologies while navigating industry challenges and complexities.

Key Points: 
  • Hear about differences shaping the industry by geography and how biotech and biopharma companies are approaching key issues differently.
  • Attendees will hear about the keys to success and prepare to successfully navigate the evolving drug development landscape.
  • In this webinar, the panel of experts will highlight findings from the pharma R&D report and go beyond the data to explain what they mean for drug developers across the globe.
  • Join this webinar to get insights into how clinical research professionals are approaching key issues and where the industry is headed.

Exyte with robust 6M/2023 results: sales growth of almost 11% to 3.7 billion euros year-on-year

Retrieved on: 
Tuesday, September 5, 2023
Semiconductor, Data, Arbutus Biopharma, EBIT, Cell, Sale, EBITDA, Acquisition, Engineering, OSM, Growth, Data center management, Pharmaceutical industry, Marketing, Video game, Exyte

In the first six months of 2023 Exyte recorded a growth in sales of almost 11% to €3.7 billion (6M/2022: €3.4 billion).

Key Points: 
  • In the first six months of 2023 Exyte recorded a growth in sales of almost 11% to €3.7 billion (6M/2022: €3.4 billion).
  • "In the first half of 2023 we were able to pursue our growth path with solid sales growth and increased financial earnings.
  • In 6M/2023 sales generated in the Advanced Technology Facilities segment grew by around 8% to €3.1 billion year-on-year (6M/2022: €2.9 billion).
  • After a particularly strong prior-year period, Exyte achieved an order intake of €2.9 billion (6M/2022: €4.2 billion).